Symbicort Turbuhaler 320 mikrograma/9 mikrograma po inhalaciji, prašak inhalata โครเอเชีย - โครเอเชีย - HALMED (Agencija za lijekove i medicinske proizvode)

symbicort turbuhaler 320 mikrograma/9 mikrograma po inhalaciji, prašak inhalata

astrazeneca d.o.o., radnička cesta 80, zagreb, hrvatska - budezonid formoterolfumarat dihidrat - prašak inhalata - 320 mikrograma + 9 mikrograma - urbroj: jedna inhalacijska doza sadrži 320 mikrograma budesonida i 9 mikrograma formoterolfumarat dihidrata

Symbicort Turbuhaler 80 mikrograma/4,5 mikrograma po inhalaciji, prašak inhalata โครเอเชีย - โครเอเชีย - HALMED (Agencija za lijekove i medicinske proizvode)

symbicort turbuhaler 80 mikrograma/4,5 mikrograma po inhalaciji, prašak inhalata

astrazeneca d.o.o., radnička cesta 80, zagreb, hrvatska - budezonid formoterolfumarat dihidrat - prašak inhalata - 80 mikrograma + 4,5 mikrograma - urbroj: jedna inhalacijska doza sadrži 80 mikrograma budesonida i 4,5 mikrograma formoterolfumarat dihidrata

Symbicort 160 mikrograma/ 4,5 mikrograma po potisku, stlačeni inhalat, suspenzija โครเอเชีย - โครเอเชีย - HALMED (Agencija za lijekove i medicinske proizvode)

symbicort 160 mikrograma/ 4,5 mikrograma po potisku, stlačeni inhalat, suspenzija

astrazeneca d.o.o., radnička cesta 80, zagreb, hrvatska - budezonid formoterolfumarat dihidrat - stlačeni inhalat, suspenzija - 160 mcg/ 4,5 mcg - urbroj: jedna doza po potisku sadrži: 160 mikrograma budezonida po potisku i 4,5 mikrograma formoterolfumarat dihidrata po potisku

Symbicort 80 mikrograma/2,25 mikrograma po potisku, stlačeni inhalat, suspenzija โครเอเชีย - โครเอเชีย - HALMED (Agencija za lijekove i medicinske proizvode)

symbicort 80 mikrograma/2,25 mikrograma po potisku, stlačeni inhalat, suspenzija

astrazeneca d.o.o., radnička cesta 80, zagreb, hrvatska - budezonid formoterolfumarat dihidrat - stlačeni inhalat, suspenzija - 80 mikrograma + 2,25 mikrograma - urbroj: jedna isporučena doza (iz aktivatora) sadrži 80 mikrograma budezonida i 2,25 mikrograma formoterolfumarat dihidrata po potisku

Brilique สหภาพยุโรป - โครเอเชีย - EMA (European Medicines Agency)

brilique

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antitrombotska sredstva - brilique, propisana u suradnji s ацетилсалициловой kiselina (ask), prikazana je za prevenciju атеротромботических događaja kod odraslih pacijenata withacute koronarni sindrom (acs) ora priča infarkta miokarda (im) i visokim rizikom za razvoj атеротромботических eventbrilique, uvedene zajedno sa acetil salicilna kiselina (ask), prikazana je za prevenciju атеротромботических događaja kod odraslih pacijenata s анамнезом infarkta miokarda (im dogodio ne manje od godine) i visokim rizikom od razvoja događaja атеротромботических.

Bydureon สหภาพยุโรป - โครเอเชีย - EMA (European Medicines Agency)

bydureon

astrazeneca ab - eksenatid - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - bydureon navodi u odrasle osobe od 18 i više godina s dijabetesom tipa 2 za bolju kontrolu glukoze u kombinaciji s drugim glukoze, smanjuje lijekova pri terapije kada se koristi zajedno s prehrane i vježbe ne pruža adekvatnu kontrolu glukoze (vidi odjeljak 4. 4, 4. 5 i 5. 1 za dostupne podatke o različitim kombinacijama). bydureon je indiciran za liječenje šećerne dijabetesa tipa 2 u kombinaciji sa:metforminsulphonylureathiazolidinedionemetformin i sulphonylureametformin i thiazolidinedionein odraslih, koji nisu postigli adekvatnu glikemijski kontrole na maksimalno переносимой doze tih oralne terapije.

Byetta สหภาพยุโรป - โครเอเชีย - EMA (European Medicines Agency)

byetta

astrazeneca ab - eksenatid - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - Баеты indiciran za liječenje tipa 2 dijabetesa u kombinaciji sa:metforminom;sulfonilureje;тиазолидиндионы;metforminom i sulfonilurejom;metforminom i тиазолидиндионом;kod odraslih, koji nisu postigli adekvatnu glikemijski kontrole na maksimalno переносимой doze tih oralne terapije. Баеты također je prikazan kao dodatna terapija za базальному inzulin ili bez метформина i / ili пиоглитазоном kod odraslih, koji nisu postigli adekvatnu kontrolu glukoze s tim agentima.

Edistride สหภาพยุโรป - โครเอเชีย - EMA (European Medicines Agency)

edistride

astrazeneca ab - dapagliflozin propandiol monohidrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lijekovi koji se koriste u dijabetesu - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. osim drugih lijekova za liječenje šećerne bolesti tipa 2 . for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Faslodex สหภาพยุโรป - โครเอเชีย - EMA (European Medicines Agency)

faslodex

astrazeneca ab - fulvestrant od - neoplazme dojki - endokrini terapija, anti-estrogeni - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. u pre - ili perimenopauzi, u sveobuhvatnoj liječenju s palbociclib treba kombinirati s luteinizirajućeg hormona releasing hormon (lhrh) agonist.

Forxiga สหภาพยุโรป - โครเอเชีย - EMA (European Medicines Agency)

forxiga

astrazeneca ab - dapagliflozin propandiol monohidrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lijekovi koji se koriste u dijabetesu - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. osim drugih lijekova za liječenje šećerne bolesti tipa 2 . for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.